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Abstract
Background: Psychosis is a common and debilitating side effect of long-term
dopaminergic treatment of Parkinson disease (PD). While clozapine is an
effective treatment, the need for blood monitoring has limited its first-line use.
Objective: Since olanzapine shows similar receptor affinity to clozapine, we
hypothesized that it might be an effective alternative to clozapine for treatment
of drug-induced psychosis (DIP) in PD, and that lower doses than usual might
make it tolerable.
Methods: In 1998-2003 we conducted a four-week, double-blind,
placebo-controlled, parallel group, fixed-dose trial of olanzapine (0, 2.5mg, or
5mg) in 23 PD patients with DIP while allowing for clinically realistic dose
adjustments of dopaminomimetic mid-study. The primary outcome measures
were Brief Psychiatric Rating Scale (BPRS) ratings scored from videotaped
interviews after study termination by an observer blinded to dose assignment
and to interview timing, and CGI (Clinical Global Impression). The Unified
Parkinson’s Disease Rating Scale motor subscale (UPDRS) was the primary
measure of tolerability.
Results: Intention-to-treat analysis found no significant differences among
treatment groups in study completion or serious adverse events. However, a
disproportionate number of olanzapine vs. placebo subjects reported mild side
effects (p<0.04), many citing motor worsening. Fourteen patients completed
the study (seven on placebo, two on 2.5mg olanzapine, five on 5mg
olanzapine). In study completers, analysis by repeated measures ANOVA
revealed no significant difference between olanzapine and placebo groups in
BPRS psychosis reduction (p=0.536), parkinsonism (p=0.608), or any other
measured parameters (CGI, MMSE, Beck Depression Inventory, Hamilton
Depression score, PDQ39, Schwab-England ADL assessment, and sleep
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scores).
Conclusion: This study adds to other evidence that olanzapine is ineffective
in treating medication-induced psychosis in Parkinson disease.
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Introduction
Drug-induced psychosis (DIP) is a significant and disabling
complication of long-term treatment of Parkinson disease
(PD), affecting a large minority of PD patients receiving chronic dopaminergic therapy1. Visual hallucinations are the most
commonly reported psychotic phenomena in this population,
with auditory, tactile, somatic, and olfactory hallucinations
being much less common. Delusions, when they occur, often
antedate visual hallucinations and commonly are paranoid or
persecutory in nature2,3. In addition to the increased caregiver
burden caused by psychosis and its sequelae, hallucinations in
the context of chronically treated PD tend to be progressive
in nature, resulting in increased propensity for nursing home
placement and subsequent higher mortality4,5. These sobering associations suggest aggressive management of DIP in this
population. However, either dose reduction of antiparkinsonian medications or addition of traditional neuroleptics usually
increases parkinsonian motor disabilities. Atypical antipsychotics, with their comparatively lower incidence of parkinsonism
in schizophrenia, have potential advantages for treatment of
hallucinations in this sensitive population1.
Until recently, the only treatment proven with randomized,
placebo-controlled studies to reduce DIP has been clozapine,
an agent that does not worsen motor function6–8. Despite these
favorable data, use of clozapine has been limited secondary to
its rare but potentially serious risk of agranulocytosis and the
consequent necessity for frequent blood draws1. Thus alternative treatments have been eagerly sought.
Quetiapine has become the most commonly prescribed antipsychotic in DIP9. Although double-blind, placebo-controlled
trials of quetiapine in PD confirmed it is well tolerated in terms
of motor side effects, it has not proven significantly more effective than placebo in treating psychosis10–15, and a head-to-head
comparison found clozapine superior to quetiapine16. Ziprasidone showed some benefit in open-label experience17, including
in a random-assignment open comparison to clozapine18. However, ziprasidone can cause motor side effects in PD and is not
generally considered standard therapy for DIP1,19. Other treatments, such as ondansetron, acetylcholinesterase inhibitors,
and electroconvulsive therapy are supported by limited data
in idiopathic Parkinson disease but are generally not viewed
as first-line therapy1,19. Recently, a phase III clinical trial of a
serotonin 5HT2A inverse agonist, pimavanserin, showed benefit
over placebo, but the drug will not be available in the U.S. at
least until late 201420–22.
Clozapine’s antipsychotic efficacy is often attributed to its D4
receptor antagonism. It is also posited that its robust 5HT2A receptor antagonism, especially in relation to its relatively weaker
D2 receptor blockade, actually increases dopamine transmission in prefrontal cortical and nigrostriatal projections23. This

may account for the cognitive improvement as well as paucity
of extrapyramidal adverse events observed in clozapine-treated
patients with dopaminomimetic-induced psychosis23,24. Olanzapine, therefore, with its ostensibly similar receptor binding
profile to clozapine at D2, D4, and serotonergic receptors (especially 5HT2A and 5HT2C), and muscarinic sites, provides a
theoretically encouraging alternative to clozapine in this fragile
population25.
An initial open study of olanzapine in Parkinson disease revealed
antipsychotic benefit without motor deterioration when drug
dosage was optimized in a slow titration (mean daily dose at end
of study was 6.5mg) and dopaminomimetic dose adjustments
were allowed26. Aarsland and colleagues replicated these findings
in a relatively more challenging population of Parkinson disease patients with and without dementia27. Several other small,
open-label studies of olanzapine, however, have demonstrated
antipsychotic benefit but at the expense of intolerable worsening of gait and bradykinesia, frequently leading to premature
termination of the drug28–30. Another small open-label trial and
case report series suggested unacceptable Parkinsonian motor
deterioration in the context of dubious antipsychotic efficacy31,32. Later, two double-blind placebo-controlled trials revealed
equivocal antipsychotic benefit and problematic motor decline
in PD patients with DIP treated with 2.5–15mg/day olanzapine
(mean final doses 4.1–4.6mg/day)33,34. As a result, experts have
recommended against the use of olanzapine in PD1,19.
None of these studies, however, were parallel-group fixed-dose
trials, and some allowed for neuroleptic dose in the same range
as approved for schizophrenia; experience with clozapine suggests that an effective antipsychotic dose in PD is often an order of magnitude less than that typical for schizophrenia treatment. In addition, the two double-blind placebo-controlled
trials did not permit adjustments of subjects’ dopaminomimetics, which might have alleviated motoric side effects. Finally, some of the studies cited were terminated prematurely due
to side effects. Given that the only marketed drug for which
efficacy has been shown is clozapine, demonstrating efficacy
for an alternative agent would be important, and a fixed low
dose of olanzapine (2.5mg/day) may allow a reasonably low
incidence of side effects if dopaminomimetic dose adjustments
are allowed. We discuss here the findings of a double-blind,
placebo-controlled study of fixed, low-dose olanzapine for
treatment of DIP in the context of flexible dopaminomimetic
dosing. The hypothesis was that olanzapine given in this fashion would reduce DIP in patients with idiopathic PD significantly more than would a placebo, without causing intolerable
motor worsening.
Methods and materials
The completed CONSORT checklist35,36 and the original study
protocol are available in the Data Files.
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Ethics statement
All patients gave written informed consent to participate in the
study, which was approved by the Washington University Human Studies Committee (approval # 97-0366). In most cases
an appropriate surrogate decision maker also consented. FDA
approval was through IND # 53,556. This trial concluded in
2003, so it is exempt from the current ICMJE requirement of
prospectively registering clinical trials.
Patient selection
Twenty-four patients were recruited from the Washington
University Movement Disorders Center from February 1998
to October 2003. Patients were examined by a movement disorders specialist and diagnosed with idiopathic PD based on
presence of at least two of three cardinal manifestations of the
disease (rigidity, bradykinesia, rest tremor), response to levodopa or a dopamine agonist, and absence of historical or examination features suggesting secondary parkinsonism. Subjects
were treated with levodopa and were experiencing clinically significant hallucinations or delusions, as judged by their treating
neurologist or psychiatrist and by the investigator (KJB). Subjects were required to be over 30 years old and have a caregiver
who could provide a reliable report. At study entry, patients
were required to be treated with the lowest clinically acceptable
dose of dopaminomimetic. Patients treated only with a dopamine agonist were not entered in the study, as it was deemed
more clinically appropriate to try a switch to levodopa before
adding an antipsychotic. Exclusion criteria included a Folstein
Mini-Mental State Examination (MMSE) score < 2237, pregnancy, concurrent diagnosis of delirium (unless clearly explained by dopaminomimetics), catatonia or neuroleptic malignant syndrome (NMS)-like syndrome, other confounding
central nervous system (CNS) illness or systemic illness with
potential CNS effects, antipsychotic use within the last month
predating study enrollment (within the past six months for depot neuroleptics), history of olanzapine sensitivity, or any expectation of significant medical or surgical intervention within
six weeks after enrollment. Subjects were also excluded if severity of psychosis warranted hospitalization or if, in the investigator’s judgment, psychosis severity would have made randomization to placebo inappropriate.
Treatment protocol
Patients were randomized 1:1:1 to treatment with placebo or
either of two doses of olanzapine. At study initiation, treatment groups consisted of a placebo arm, a 5mg arm, in which
patients received this dosage nightly throughout the four weeks
of investigation, and a 10mg arm, in which patients received
5mg for the first week and 10mg thereafter. Subjects received
matched tablets or capsules provided by Lilly Research Laboratories (Indianapolis, IN), who provided the investigator with
sealed, sequentially numbered envelopes containing the medication identity for each subject. The envelopes were not opened

until after all data were collected and reviewed for accuracy, and
after all decisions about statistical analysis were final, so that
both investigators and patients were blind to intervention assignment. The randomization was done by Lilly. KJB enrolled
subjects and patients were assigned to treatment packages
sequentially by enrollment date.
After the first five patients were enrolled, an interim safety analysis was conducted by a reviewer otherwise not involved in the
study, in light of reports published since the study initiation
that higher olanzapine doses caused intolerable exacerbation of
parkinsonism in PD. Though serious adverse events were no
more common in the treatment groups than in the placebo
group, it was decided at this time that the two active treatment
arms would be changed to fixed doses of 2.5mg and 5mg olanzapine, maintained throughout the four weeks of study. New
treatment packages were received and the blind was maintained
until after data analysis, as above. No other changes to the protocol were made. See Table 1 for a summary of the final study
design. The study was planned for 10 subjects in each of three
dose arms. This would produce 90% power (at alpha = 0.05)
to detect a change of the magnitude and variability seen in the
Wolters et al.26 report.
Subjects received a baseline evaluation that involved a full
psychiatric, neurologic, and medical history and examination, CGI (Clinical Global Impression) by MD38, PDQ-39, a
self-rated quality-of-life measure for PD39, videotaped interview for later BPRS (Brief Psychiatric Rating Scale) rating
blind to drug dose and blind to which visit was being rated40,
Schwab-England ADL assessment41, UPDRS (Unified Parkinson’s Disease Rating Scale), section III (motor)42, MMSE37,
HDRS (Hamilton Depression Rating Scale)43, BDI (Beck Depression Inventory)44, and patient/caretaker reported hours and
quality of sleep. Repeated measures at the two-week interim
visit and the final four-week evaluation included CGI (by MD,
patient, and caretaker), videotaped interview for later blinded
BPRS, Schwab-England ADL assessment, UPDRS, MMSE,
PDQ-39, BDI, sleep questionnaire, and pill counts. All assessments were done at Washington University Medical Center.
Primary efficacy measures were CGI scores and BPRS ratings
of psychosis. At each visit, the coordinator interviewed the patient during videotaping using a semi-structured interview designed to facilitate later scoring of psychopathology using the
BPRS40,45,46. After all subjects had completed participation, the
videotaped segments were edited to remove references to date
or study visit. Author KJB in consultation with a BPRS expert
(John G Csernansky, MD) wrote rules for rating “motor retardation” and other BPRS items potentially influenced by parkinsonism (see Supplementary materials), and trained author
MJN in BPRS ratings. Videotaped segments were reviewed in
random order by MJN, who was unaware of drug assignment

Page 4 of 11

F1000Research 2013, 2:150 Last updated: 11 JUL 2013

Table 1. Summary of final study design.
Baseline

Weeks 1–2

2 week visit

Weeks 3–4

4 week visit

Clinical evaluation;
randomize

Placebo
2.5mg 5mg

Clinical evaluation; ↑
dopaminometic, if indicated

Placebo
2.5mg 5mg

Clinical evaluation; return to
routine clinical care

This table summarizes the study design and timing of assessments and interventions for the last 19 subjects enrolled in the
study. ↑ dopaminometic: dose increase allowed for antiparkinsonian medication, if parkinsonism had worsened since starting
the study. See Methods and Figure 1 for further details.

or treatment duration at the time of the visit. BPRS ratings
used the anchored BPRS and each item was scored from 1–740.
Secondary efficacy measures included the PDQ-39, ADL assessments (Schwab-England and UPDRS), BDI, and sleep log.
Primary safety measures were UPDRS motor ratings, sleep logs,
and MMSE in addition to clinical review of systems.
Statistical analysis
Prior to unblinding of drug codes, the decision was made to
analyze data from weeks 0–2 and weeks 2–4 separately. This
a priori decision was made since adjustment of dopaminomimetics was allowed at the interim (week 2) visit. Change from
0 to 2 weeks was chosen to be the primary test of efficacy. An
intention-to-treat (ITT) analysis was performed on all enrolled
subjects. However, since some subjects dropped out without
completing outcome measures at a follow-up visit, the ITT
analysis was limited to between-group comparisons of dropout
rate, serious adverse events, and reported worsening of parkinsonism or other side effects judged to be at least mild in se-

verity. Adverse events, side effects, and study withdrawal were
compared between groups using the chi-squared test.
For those subjects with data at both time points of an epoch,
primary and secondary efficacy measures were tested separately
for the two epochs using repeated-measures ANOVA to compare the groups. The decision was made a priori to include
any subject in these analyses if that patient had taken at least
one week’s worth of drug during an epoch and returned for a
follow-up visit. A secondary post hoc analysis of the data from
trial completers was also performed across all three visits using repeated-measures ANOVA. Statistical computations used
STATISTICA 7.1 (StatSoft, Inc., Tulsa, OK) or Excel (Microsoft, Redmond, WA).
Results
Baseline characteristics
A total of 24 patients were enrolled (see Figure 1). Though the
original study design sought enrollment of 30 patients, the

Assessed for eligibility (n=24)

Randomized (n=24)

Allocated & received intervention (n=15)

Allocated to & received
placebo (n=9)

Discontinued placebo
due to death (n=1)
Discontinued due to
lack of efficacy (n=1)

Analyzed (n=9)

Allocated to 2.5mg
(n=6)

Discontinued due to
motor SEs (n=2)
Discontinued due to
minor (non-motor) SEs
(n=2)

Analyzed (n=3)
Excluded from analysis
due to lack of f/u (n=3)

Allocated to 5mg
(n=8)
Discontinued due to motor
SEs (n=1)
Discontinued due to SAE
(delinium) (n=1)
Discontinued due to
“cure” (n=1)
Analyzed (n=6)
Excluded from analysis
due to lack of f/u (n=2)

Allocated to 10mg
(n=1)

NO
discontinuations

Analyzed (n=0)
Excluded from analysis
due to change in study
randomization (n=1)

Figure 1. CONSORT flowchart.
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study was terminated early, secondary to the growing body
of literature questioning the safety of olanzapine in the treatment of DIP as well as the increasing difficulty in enrolling
antipsychotic-naive patients.
Only one subject was treated with 10mg (one other was randomized to the 10mg group, but was treated only for one week,
so received only 5mg doses). His hallucinations were rated
“very much improved” at the study end; he required no adjustment in dopaminomimetic dose mid-study and no side effects
were observed. This 10mg subject was not included in statistical analyses. In the remaining 23 subjects, no significant imbalances were present at baseline between placebo and treatment
groups on any demographic characteristic or any psychiatric or
neurologic measure (Table 2).
Intention-to-treat analyses
The intention-to-treat analyses did not show significant differences between groups except for incidence of mild side effects
(p<0.04) (Table 3). While spontaneous report of motor side
effects was not statistically significant between groups, a disproportionate number of olanzapine vs. placebo group subjects
who withdrew did so secondary to reported motor side effects
(0% of placebo withdrawers vs. 21% of olanzapine withdrawers). Nine subjects did not complete the study: two from the
placebo group, four from the 2.5mg olanzapine group, and
three from the 5mg olanzapine group. In the placebo group,
one patient died of myocardial infarction and another withdrew from the study secondary to lack of efficacy. In the 5mg

olanzapine group, two reported serious adverse events and a
third discontinued her medication following the first dose, declaring herself “cured”. Of the 5mg subjects who withdrew for
serious adverse events, one was hospitalized with delirium three
weeks into the study; the other withdrew after day six due to
hospitalization with hip fracture and pneumonia, and reported
worsening PD symptoms prior to dropout. Of the four subjects
who dropped out of the 2.5mg olanzapine group, two withdrew due to worsening parkinsonian symptoms, one secondary to unspecified side effects, and one secondary to “feeling
confused”. Only two subjects in the 2.5mg group completed
the study, both requiring increases of their levodopa dose at
their interim visit. One each in the placebo and 5mg olanzapine arms also required levodopa adjustment at their two-week
assessment. Retention and attrition of study subjects is summarized in Table 3 and Figure 1.
To assess adequacy of blinding, both the primary investigator
and study subjects were asked on study completion (or dropout) to guess the identity of administered medication (i.e., olanzapine vs. placebo). Both investigator and patient were much
more likely than chance would predict to correctly guess the
identity of administered medication (for investigator, χ2=12.29,
p=0.0021; for study subjects, χ2=6.94, p=0.0312). However,
the videotape rater had no information about side effects.
Negative results from a randomized controlled trial of olanzapine
for psychosis in Parkinson disease: data, CONSORT checklist
and initial study protocol
5 Data Files
http://dx.doi.org/10.6084/m9.figshare.730446

Table 2. Patient characteristics at baseline.
Olanzapine
Measure

Placebo (n=9) 2.5mg (n=6) 5mg (n=8)

p value

Age

71.3 (6.5)

70.7 (8.1)

72.4 (4.8)

0.882

MMSE

26 (2.6)

27 (3.6)

27 (2.7)

0.976

BPRS-T

34.8 (5.9)

34.3 (5.4)

33.4 (3)

0.874

BPRS-P

7.9 (2)

9 (3)

7.8 (2.1)

0.633

UPDRS,
30 (11)
motor score

27.5 (13.1)

31 (11.6)

0.855

PDQ-39

53 (25.7)

59 (15.9)

59 (27.3)

0.867

BDI

10.1 (6)

9.8 (6)

12.6 (9.2)

0.738

HAM-D

8.7 (6.1)

5.3 (1.6)

11.6 (7.6)

0.177

CGI

4.1 (0.9)

3.2 (1)

3.9 (0.8)

0.161

INS

4.2 (4)

4 (2.1)

2.6 (2.6)

0.566

HYPINS

1.5 (1)

2.3 (1.9)

2.6 (2.1)

0.446

SEADL

76 (15)

72 (24)

75 (17)

0.918

Values are given as mean (SD). MMSE, Folstein mini mental test examination;
BPRS-T, Brief Psychiatric Rating Scale total score; BPRS-P, psychosis
subscale; UPDRS, Unified Parkinson’s Disease Rating Scale; PDQ-39,
Parkinson’s disease quality of life questionnaire; BDI, Beck depression
inventory; HAM-D, Hamilton depression rating scale; CGI, Clinical global
impression; INS, Insomnia score; HYP, Hypersomnia score; SEADL,
Schwab-England ADL assessment.

Primary planned analyses
Analysis of the psychosis subscale of BPRS scores (the more
sensitive of our primary efficacy measures) did not reveal a statistically significant difference between groups (drug doses) in
severity of psychosis in either the week 0–2 epoch (p=0.433) or
the week 2–4 epoch (p=0.393). Again, post hoc analysis in study
completers revealed no statistical significance in psychosis reduction between olanzapine (combined groups) and placebo
(p=0.536), as shown in Figure 2.

Data from the first and second epochs revealed no statistically
significant difference in parkinsonian signs across treatment
groups, as measured by the UPDRS III (week 0–2 epoch, placebo vs. 2.5mg olanzapine group p=0.172; week 2–4 epoch
p=0.677). Post hoc analysis of UPDRS motor scores comparing
olanzapine (combined groups) versus placebo across the duration of study found no significant difference in parkinsonism
among study completers (p=0.608) (Figure 3).
Analyses were repeated in like fashion for all other psychiatric
and neurological parameters (CGI impression, CGI improvePage 6 of 11
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Table 3. Subject retention and side effects by group.
Olanzapine
Placebo

2.5mg

5mg

All

# enrolled

9

6

8

23

# withdrew

2 (22%)

4 (66%) 3 (38%)

9 (39%)

0.2232

# withdrew for motor SEs

0 (0%)

2 (33%) 1 (12%)

3 (13%)

0.1712

# w/motor SE complaint

1 (11%)

2 (33%) 1 (12%)

4 (17%)

0.4863

# w/any mild SEs

2 (22%)

5 (83%) 2 (25%)

9 (39%)

*0.0356

# w/serious adverse
events

1 (11%)

0 (0%)

3 (13%)

0.3795

# included in 1st epoch

9 (100%)

3 (50%) 5 (63%)

17 (74%) 0.0640

# included in 2nd epoch

7 (78%)

2 (33%) 5 (63%)

14 (61%) 0.2232

# w/dopaminomimetic ↑

1 (11%)

2 (33%) 1 (13%)

4 (17%)

2 (25%)

p value

0.4863

Side effects (SEs) were any complaint of drug spontaneously reported by the patient,
independent of whether SE intensity was severe enough to prompt withdrawal from the
study. Serious adverse events always prompted withdrawal. SE, side effects; ↑, increase;
1st epoch, week 0–2 analysis; 2nd epoch, week 2–4 analysis, *, p<0.05.

12

ment, BPRS total, BDI, MMSE, insomnia score, hypersomnolence score, PDQ-39, and Schwab-England ADL assessment),
none of which revealed statistical significance between olanzapine groups and placebo.

BPRS psychosis sub scale

11
10
9
8
7
6
5
4
3

Week 0

Week 2

Week 4

TIME

olanzapine
placebo

Figure 2. Brief Psychiatric Rating Scale (BPRS) scores across
four week study revealed no significant difference between
placebo and olanzapine groups among study completers.
Current effect: F(2, 24)=0.64064, p=0.53573. Effective hypothesis
decomposition. Vertical bars denote 0.95 confidence intervals.
Olanzapine-blue; placebo-red.
45

UPDRS Sub scale III (motor)

40
35

30
25
20

15

Week 0

Week 2
TIME

Week 4

olanzapine
placebo

Figure 3. Unified Parkinson’s Disease Rating Scale (UPDRS)
scores across four week study revealed no significant
difference between placebo and olanzapine groups among
study completers. Current effect: F(2, 24)=0.50826, p=0.60787.
Effective hypothesis decomposition. Vertical bars denote 0.95
confdence intervals. Olanzapine-blue; placebo-red.

Discussion
The study failed to reject the null hypothesis. This could be a Type
II error, but larger studies of olanzapine also failed to demonstrate
antipsychotic efficacy of this drug in the PD population14,33. In
study completers, we did not observe the motoric exacerbation
documented in several studies in the literature28–34, but perhaps
this is a function of our allowance for dopaminomimetic increase
mid-study as well as a selection bias in some analyses for those subjects who best tolerated the medication and therefore completed the
study. After all, of the nine subjects who withdrew from the study,
a third identified a worsening of their motor disability prior to
dropout, all of whom were discovered on unblinding to have been
randomized to olanzapine. Therefore the good retrospective
accuracy of investigator and patient guesses of study drug identity
is not surprising.
The subjects enrolled are relatively typical of PD patients with
psychotic symptoms with a few exceptions. Subjects with urgent
need for treatment were not enrolled for ethical reasons. Although
mild dementia was allowed, this sample had relatively high cognitive functioning, with a mean MMSE score > 26 (Table 2). Finally, at this center, some of the patients are referred for subspecialty
movement disorders consultation, though a large fraction of the
patients are not referred and are typical of PD patients treated in
the community. With these caveats, the results appear to be generally applicable to patients with PD and psychosis.
One methodological innovation in this study was the use of
videotape to record semi-standardized interviews for later
analysis by a rater blind not only to drug assignment but also
Page 7 of 11
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to time (i.e., week 0, week 2, or week 4). The rationale was
to minimize rater expectation of improvement over time that
might reduce our power to detect significantly greater improvement in the active treatment groups. It also reduced the
likelihood of rater unblinding.

collection. KJB designed the study, supervised all aspects of the
study, takes responsibility for all aspects of the manuscript, and
performed 40% of data analysis, 40% of data collection, and
30% of manuscript preparation. All authors reviewed the manuscript.

This trial supports other evidence suggesting that olanzapine
is ineffective for relieving dopaminomimetic-induced psychotic symptoms in Parkinson disease and that it may cause
intolerable worsening of motor disability1,19. This trial also
underscores the importance of rigorous study design for the
assessment of drug effectiveness in special populations, as
we and others have not replicated the early, positive openlabel experience reported for olanzapine in this population.
If clozapine’s prominence in the clinical management of DIP
in PD is to be usurped, antipsychotic agents will have to
meet the burden of proof of double-blind, randomized,
placebo-controlled trials.
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Supplementary materials
Guidelines for rating selected BPRS items in a treatment
study of psychosis in Parkinson disease.
1. Emotional withdrawal = interpersonal relatedness during
interview.
2. Tension:
a. Ignore: rest tremors, postural tremors, chorea, athetosis,
dystonia.
b. Include: tardive dyskinesia and akathisia.
3. Depressive mood rating does not consider “pure apathy”
(i.e., apathy w/o other depressive signs or symptoms), but
apathy can contribute to the total judgment of depressive
mood if other signs or symptoms are present.
4. Hallucinatory behavior:
a. 2 = illusions and “shadow in the corner of the eye”.
b. 3 = e.g., colors on the wall.
c. ≥ 4 = definitively abnormal sensory perceptions.

5. 
Motor retardation: Speed of movement, not amplitude
(also, depressive retardation is not substantially helped by
external cues; if slowed movement is substantially helped
by external cues, then it may be more parsimoniously
attributed to PD).
6. Unusual thought content: Ratings ≥ 5 require action on
delusion.
7. Blunted affect: Rate according to scale, considering emotional variance, regardless of amplitude; remember that
flat/blunted affect is not equivalent to depressed affect.
8. Disorientation: Off by one day of week = 3.
  Motor hyperactivity: Limit rating to pressured speech and
voluntary movement; festination does not count.
Kevin J Black MD consulted with John G Csernansky MD
to write these additional rules for scoring BPRS items potentially influenced by motor signs in Parkinson disease
patients.
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The study (completed in 2003) was well designed, albeit with a relatively small sample size, and
intended to answer an important and clinically relevant question. After reviewing the manuscript I would
agree that it probably does support the notion that olanazapine may cause intolerable worsening of
motor disability but I do not think that one can draw any conclusions regarding efficacy or lack thereof
based on this study.
One element of the trial design (i.e. permitting changes in dopaminergic medications) may have created
some challenges when interpreting the data. The investigators speculated that olanzapine may be
better tolerated if adjustments in dopaminergic medications were allowed (and therefore permitted
dopaminergic medication adjustment at the 2 week visit). While this may be true, it could also increase
the chances that dopaminergic drug induced psychosis could worsen (if dopaminergic medication were
increased in an effort to improve motor worsening). This could potentially be a "set up" for decreased
efficacy (if dopaminergic medications were changed more frequently in active vs. placebo). It is noted
that medications were adjusted in one of the placebos, two of the 2.5 mg active and one of the 5 mg
active. The authors note that there was an apriori decision to analyze data from weeks 0-2 and 2-4
separately. Change from 0-2 weeks was chosen to be the primary test of efficacy, apparently in order to
limit the confound of changes in dopaminergic medications allowed at week two. However, one could
question if 2 weeks is long enough to demonstrate efficacy.
In addition, a series of unplanned events contributed to challenges with data interpretation. These
events included a change in design after study initiation, lower than expected enrollment and high
dropout rate.
The change in study design was a decrease in study drug dosage after enrollment of 5 subjects ("in light
of reports published since study initiation that higher olanzapine doses cause intolerable exacerbation of
parkinsonism in PD"). This resulted in one subject being excluded from analyses (see below) and
perhaps, decreased the chance of demonstrating study drug efficacy (if higher dosages were required).
Only 24 (of an anticipated 30) subjects were enrolled and 9 withdrew (39%) which is a fairly high dropout
rate. One of the 24 subjects was not included in the analyses because he was the only one to receive
the initially planned dosage of 10 mg.
While spontaneous reports of motor side effects were not statistically significant between groups, a
disproportionate number of olanzapine vs. placebo who withdrew did so due to motor side effects. This
finding does suggest that olanzapine may be associated with worsening motor function. However this
may not be true for every patient, as exemplified by the one subject who was the only to receive the
initially planned dosage of 10 mg. He had no worsening of motor function (and an improvement in
psychosis).
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